Wearable devices can detect early signs of neurodegenerative diseases by continuously capturing subtle changes in movement, physiology, and behavior that precede clinical diagnosis. These devices transform raw sensor streams into digital biomarkers that researchers and clinicians can use for screening, monitoring progression, and evaluating treatment response.
Physiological and behavioral signals
Sensors such as accelerometers and gyroscopes identify changes in cadence, stride length, tremor amplitude, and postural stability relevant to Parkinsonian syndromes. Ray Dorsey at University of Rochester has demonstrated the value of remote monitoring for Parkinson’s disease by comparing home-based sensor data with clinic assessments, showing that daily-life recordings reveal fluctuations missed in brief clinic visits. Wearables that track heart rate variability, sleep architecture, and nighttime activity detect patterns associated with Alzheimer’s disease risk. Yo-El S. Ju at Washington University in St. Louis has linked sleep fragmentation and reduced slow-wave sleep to amyloid accumulation and cognitive decline, suggesting consumer and medical wearables can provide early warning signals when analyzed alongside clinical data.
From signals to clinical meaning
Algorithms convert sensor streams into features such as gait symmetry, tremor frequency, or sleep fragmentation, then map those features to disease-relevant endpoints using machine learning trained on labeled clinical cohorts. Michael J. Fox Foundation-funded studies have shown that combining multiple modalities improves sensitivity for prodromal Parkinson’s features compared with single-sensor approaches. The National Institute on Aging supports research integrating wearable-derived measures with fluid and imaging biomarkers for Alzheimer’s disease, which helps distinguish age-related variation from disease-specific changes.
Relevance arises because neurodegeneration often begins years before functional impairment. Detecting early motor or non-motor signs can accelerate intervention, clinical trial enrollment, and lifestyle or pharmacologic strategies that may delay disability. Causes of detectable changes include neuronal loss in motor and sleep-regulatory circuits, autonomic dysfunction affecting heart rate, and compensatory behavioral shifts such as reduced activity.
Consequences extend beyond clinical benefit. Privacy, algorithmic bias, and unequal access are significant issues: devices validated in high-resource populations may underperform in different cultural or territorial settings where gait, daily routines, or smartphone use differ. Regulatory oversight from agencies such as the U.S. Food and Drug Administration and transparent validation against clinical gold standards are essential to translate wearable signals into trustworthy diagnostic tools.